Rongliflozin
Appearance
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H27ClO7 |
Molar mass | 450.91 g·mol−1 |
3D model (JSmol) | |
| |
|
Rongliflozin is an SGLT2 inhibitor developed as a potential treatment for diabetes.[1][2]
References
[edit]- ^ Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, et al. (May 2020). "A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State". Clinical Therapeutics. 42 (5): 892–905.e3. doi:10.1016/j.clinthera.2020.03.007. PMID 32265061.
- ^ Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al. (February 2020). "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus". Diabetes, Obesity & Metabolism. 22 (2): 191–202. doi:10.1111/dom.13887. PMID 31588657.